Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献

{"title":"Resultados e incidencia de hipotiroidismo tras el tratamiento del hipertiroidismo con yodo radiactivo a dosis bajas","authors":"K.-H. Lin ,&nbsp;J.-C. Wu ,&nbsp;M.-C. Wu","doi":"10.1016/j.remn.2024.500056","DOIUrl":"10.1016/j.remn.2024.500056","url":null,"abstract":"<div><h3>Objective</h3><div>The study aimed to analyze the outcome of low-dose radioactive iodine (RAI) treatment for hyperthyroidism, disclose whether age and gender influence the outcome, and determine the incidence and onset time of hypothyroidism following low-dose RAI.</div></div><div><h3>Material and methods</h3><div>A total of 158 patients who received doses less than 370<!--> <!-->Mbq RAI were enrolled in the study. Treatment outcome and incidence of hypothyroidism were compared between different gender (45 male vs. 113 female), age (77 patients ≥<!--> <!-->45<!--> <!-->years old vs. 81 patients &lt;<!--> <!-->45<!--> <!-->years old) and dose (39 patients receiving higher doses RAI vs. 119 receiving lower dose with a cutoff of 222<!--> <!-->MBq) groups. Treatment outcomes were categorized into post-treatment hypothyroidism, treatment failure (persistent hyperthyroidism), and euthyroidism. In those becoming hypothyroid, time to develop hypothyroidism was calculated for cumulative incidences over time.</div></div><div><h3>Results</h3><div>Out of 158 patients, 47 (29.7%) developed hypothyroidism, 101 (63.9%) had treatment failure, and 10 (6.3%) remained euthyroid after treatment. Response rates (33.6% vs. 43.5%, <em>P</em> <!-->=<!--> <!-->.260) and hypothyroidism incidences (26.9% vs. 38.5%, <em>P</em> <!-->=<!--> <!-->.170) did not differ significantly between lower and higher dose groups, neither between lower and higher age groups (<em>P</em> <!-->=<!--> <!-->.69 in response rates and <em>P</em> <!-->=<!--> <!-->.75 in hypothyroidism incidence). Females exhibited higher response rates (42.5% vs. 20.0%, <em>P</em> <!-->=<!--> <!-->.008) and hypothyroidism incidence (46.3% vs. 13.3%, <em>P</em> <!-->=<!--> <!-->.004) compared to males. Hypothyroidism onset occurred at a mean of 24.0<!--> <!-->±<!--> <!-->29.2 months, and the cumulative incidences over time were 47% and 60% in six and twelve months, respectively.</div></div><div><h3>Conclusions</h3><div>Low-dose RAI has a low response rate for treating hyperthyroidism. Although there may be a lower incidence of hypothyroidism following low-dose RAI compared to high-dose RAI, hypothyroidism may occur early after treatment. Besides, females have higher response rates but more incidence of hypothyroidism. The balance between the risks and benefits of using low-dose RAI should be taken into deliberate consideration.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500056"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valor de la PET/TC con [18F]FDG en el diagnóstico y grado histopatológico de los adenomas colorrectales incidentales","authors":"Z. Qi ,&nbsp;K. Tang ,&nbsp;X. Lu ,&nbsp;Y. Zhu ,&nbsp;N. Xu","doi":"10.1016/j.remn.2024.500075","DOIUrl":"10.1016/j.remn.2024.500075","url":null,"abstract":"<div><h3>Purpose</h3><div>Colorectal adenomas (CRAs) are at a higher risk of progressing to colorectal cancer (CRC) as their histological grade increases. Herein, this study investigated the relationship between the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography-computed tomography ([¹⁸F]FDG PET/CT) and the histological grades of CRAs and constructed the optimal regression model for distinguishing between different histological grades.</div></div><div><h3>Methods</h3><div>This study retrospectively analyzed the data of 153 patients with CRAs who had colorectal [¹⁸F]FDG uptake incidentally found on PET/CT. The patients were categorized into low-grade intraepithelial neoplasia (LGIN) and high-grade intraepithelial neoplasia (HGIN) groups based on their histological grade. After the analysis of the relationship between SUVmax measured on preoperative [¹⁸F]FDG PET/CT scans and histological grades, receiver-operating characteristic (ROC) curves were analyzed to determine the optimal cut-off values for distinguishing between the two groups. Common clinical and pathological factors were included and subjected to univariate and multivariate logistic regression analyses to identify independent risk factors. A diagnostic model integrating SUVmax and several risk factors was developed with the multivariate logistic regression analysis.</div></div><div><h3>Results</h3><div>SUVmax was significantly different between the two groups (<em>P</em> <!-->&lt;<!--> <!-->.001) and increased with an elevation in the malignancy degree. The area under the ROC curve (AUC) for identifying LGIN and HGIN was 0.796, and the AUC of the combination model was 0.822. Furthermore, SUVmax was an independent risk factor for distinguishing between different histological grades in pairwise comparisons.</div></div><div><h3>Conclusion</h3><div>The regression model involving SUVmax on [¹⁸F]FDG PET/CT can distinguish between histological grades of CRAs, which therefore can be used as a noninvasive tool for the accurate diagnosis of CRAs and assist in developing patient-specific treatment strategies before surgery.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500075"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparación de la estadificación mediante [68Ga]Ga-PSMA-11 PET/TC y los resultados anatomopatológicos en pacientes con cáncer de próstata de riesgo intermedio y alto tratados con prostatectomía radical y linfadenectomía pélvica","authors":"J.J. Rosales ,&nbsp;V. Betech Antar ,&nbsp;F. Mínguez ,&nbsp;F. Pareja ,&nbsp;F. Guillén ,&nbsp;E. Prieto ,&nbsp;G. Quincoces ,&nbsp;F. Díez Caballero ,&nbsp;B. Miñana ,&nbsp;J.L. Pérez-Gracia ,&nbsp;M. Rodríguez-Fraile","doi":"10.1016/j.remn.2024.500076","DOIUrl":"10.1016/j.remn.2024.500076","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the diagnostic accuracy of [⁶⁸Ga]Ga-PSMA-11 PET/CT (PET-PSMA) in local and loco-regional nodal staging compared with histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy (RP) and pelvic lymph node dissection (PLND).</div></div><div><h3>Materials y methods</h3><div>A total of 122 intermediate- and high-risk prostate cancer (PCa) patients staged with PET-PSMA and treated with RP (36/122) and RP plus PLND (86/122) from December 2018 to December 2023 were included. Visual and semiquantitative analysis findings using the SUVmax of the molecular imaging were correlated with histopathological results.</div></div><div><h3>Results</h3><div>The primary tumor was visible by PET-PSMA in 96.7% of the patients. A positive correlation was found between PSA levels and SUVmax (Spearman's r: 0.303, p&lt;<!--> <!-->0.001). PET-PSMA detected nodal involvement in 25/89 patients (28.08%). The sensitivity, specificity, and diagnostic accuracy of PET-PSMA for detecting nodal involvement were 75%, 82.2%, and 80.9%, respectively. Patients with PSA levels<!--> <!-->&gt;20 ng/ml, Gleason score ≥7b, ISUP grade<!--> <!-->&gt;2, and extracapsular extension showed significantly higher SUVmax values. No differences were observed in SUVmax between risk groups or in other histopathological variables.</div></div><div><h3>Conclusions</h3><div>PET-PSMA is an effective tool for the initial staging of intermediate- and high-risk PCa. SUVmax values were significantly higher in patients with unfavorable clinical features.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500076"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Falsa imagen de recidiva ganglionar en la PET/TC con [68Ga]Ga-PSMA-11. Importancia del protocolo de adquisición","authors":"C. Castillo-Arias ,&nbsp;D. Vas ,&nbsp;E. García ,&nbsp;K. Quintero ,&nbsp;M. Tormo ,&nbsp;P. Paredes","doi":"10.1016/j.remn.2024.500077","DOIUrl":"10.1016/j.remn.2024.500077","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500077"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hallazgos de la 18F-FDG y 11C-PIB PET/TC en estatus epiléptico en el contexto de paciente con deterioro cognitivo leve","authors":"M. Pombo-López,&nbsp;A. Bota-Bota,&nbsp;I. Martínez-Rodríguez,&nbsp;F. Gómez-de la Fuente,&nbsp;J. Jiménez-Bonilla,&nbsp;R. Quirce","doi":"10.1016/j.remn.2024.500079","DOIUrl":"10.1016/j.remn.2024.500079","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500079"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valoración de los nódulos pulmonares mediante [18F]-FDG PET/TC en inspiración profunda mantenida","authors":"M.S. Casallas Cepeda,&nbsp;S. Salcedo Cortes,&nbsp;I. Gómez Fernández,&nbsp;J. Orcajo Rincón,&nbsp;L. Reguera Berenguer,&nbsp;E.J. Ardila Manjarrez,&nbsp;J.J. Ardila Mantilla,&nbsp;V. Castillo Morales,&nbsp;J. Guzman Cruz,&nbsp;D. Zamudio Rodriguez,&nbsp;A. Marí Hualde,&nbsp;J.E. Montalvá Pastor,&nbsp;S. Álvarez Lara,&nbsp;J.C. Alonso Farto","doi":"10.1016/j.remn.2024.500074","DOIUrl":"10.1016/j.remn.2024.500074","url":null,"abstract":"<div><h3>Introduction</h3><div>The characterization of pulmonary nodules (PN) is a primary indication for [¹⁸F]-FDG PET/CT. However, respiratory movements hinder this characterization, especially for PN located in the lower lobes. Various methods have been developed to improve image resolution.</div></div><div><h3>Objective</h3><div>Our objective was to compare the diagnostic efficacy of [¹⁸F]-FDG PET/CT in deep inspiration breath-hold (DIBH) versus free-breathing corrected by software, in the evaluation of PN.</div></div><div><h3>Methods</h3><div>We prospectively analyzed 51 patients to assess PN using [¹⁸F]-FDG PET/CT in DIBH and free-breathing corrected by software. A total of 84 nodules with an average size of 10<!--> <!-->mm were analyzed, with pathological anatomy or medical treatment decisions by a multidisciplinary tumor board used as reference.</div></div><div><h3>Results</h3><div>A total of 84 PN were evaluated, comparing those in DIBH versus free-breathing, finding statistically significant differences in SUVmax values (<em>P</em>&lt;.05) (mean SUVmax 3.7 in free-breathing vs. 5.33 in DIBH). When analyzed by location in lobes, we did not find statistically significant differences, though there was a trend towards higher SUVmax values in the lower lobes. [18F]-FDG PET/CT in DIBH showed high sensitivity (95%) and negative predictive value (NPV) (92%), indicating it may be a promising tool for PN characterization.</div></div><div><h3>Conclusions</h3><div>The acquisition of [¹⁸F]-FDG PET/CT in DIBH significantly improves the sensitivity and diagnostic efficacy in the assessment of PN. Although no statistically significant differences were found based on location, there is a potential benefit for the lower lobes. These findings could support its use in clinical practice.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500074"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enfermedad por micropartículas en prótesis de cadera, a propósito de un caso","authors":"J.L. Díaz Moreno,&nbsp;I.E. Sánchez-Rodríguez,&nbsp;B. Hervás-Sanz,&nbsp;P. Notta-González,&nbsp;C. Martínez-Ramos,&nbsp;L. Gràcia-Sánchez","doi":"10.1016/j.remn.2024.500078","DOIUrl":"10.1016/j.remn.2024.500078","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500078"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papel y aplicaciones de la [18F]FDG PET/TC en la evaluación de la infección e inflamación osteoarticular. Parte II","authors":"E. Noriega-Álvarez ,&nbsp;B. Rodríguez Alfonso ,&nbsp;J.J. Rosales Castillo ,&nbsp;A. Moreno Ballesteros ,&nbsp;E. López Rodríguez ,&nbsp;S. Sanz Viedma ,&nbsp;M.P. Orduña Diez ,&nbsp;L. Domínguez Gadea","doi":"10.1016/j.remn.2024.500102","DOIUrl":"10.1016/j.remn.2024.500102","url":null,"abstract":"<div><div>[¹⁸F]FDG PET/TC is an emerging tool in the evaluation of inflammatory arthropathies, characterised by their insidious course and clinical overlap. It allows detection of subclinical inflammation, assessment of systemic involvement and quantification of metabolic parameters useful in early diagnosis and therapeutic monitoring. In rheumatoid arthritis, it correlates with clinical indices (<em>Disease Activity Score</em>), serological markers (CRP, anti-citrullinated protein antibodies) and ultrasound findings, and facilitates the identification of complications such as cardiovascular and pulmonary involvement. In spondyloarthritis, its ability to identify enthesitis and peripheral synovitis is promising, although less studied. In addition, [¹⁸F]FDG PET/TC evaluates the response to biological treatments, helping to optimise therapeutic decisions. However, its implementation faces challenges such as lack of standardised indications, incidental findings and technical artefacts. Although not routinely recommended, its usefulness in specific settings underlines the need for further studies to consolidate its role in the management of these diseases. In this manuscript, we present a brief review providing general and practical information about the role of [¹⁸F]FDG PET/TC in inflammatory osteoarticular pathology, while “Role and applications of [¹⁸F]FDG PET/CT in the assessment of osteoarticular infection and inflammation - Part I” has addressed its role in infectious osteoarticular disease.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500102"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilidad de la PET/TC con [18F]F-fluorocolina en la valoración de respuesta a la terapia antiandrogénica en pacientes con cáncer de próstata","authors":"K. Quintero ,&nbsp;E. Vila ,&nbsp;L. Ferrer-Mileo ,&nbsp;D. Vas ,&nbsp;Maria J. Ribal ,&nbsp;M. Garcia-Herreros ,&nbsp;N. Navarro ,&nbsp;M. Tormo-Ratera ,&nbsp;C. Aversa ,&nbsp;A. Vilaseca ,&nbsp;A. Farré-Melero ,&nbsp;D. Fuster ,&nbsp;P. Paredes ,&nbsp;grupo de Medicina Nuclear Clínic Barcelona (MNCB)","doi":"10.1016/j.remn.2024.500083","DOIUrl":"10.1016/j.remn.2024.500083","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the correlation between response assessment measured by PET/CT with [¹⁸F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.</div></div><div><h3>Methodology</h3><div>A retrospective study included patients with CRPC and CSPC treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (ΔSUV) between both studies and the PSA value before and at follow-up were recorded. The response to treatment was compared by PSA vs. PET, assessing their association, agreement, and correlation.</div></div><div><h3>Results</h3><div>Thirty patients were included (median age 74 years, range 68-78), 12 with CSPC and 18 with CRPC; 22 had nodal disease, and 15 had active bone disease. The average time between pre-treatment and follow-up PET/CT was 11 months (range 3.5-23).</div><div>Patients with extra-nodal metastatic disease at the beginning of treatment showed a higher correlation between PSA and ΔSUV (OR 4.375). In patients with bone disease at the start of treatment, 80% were classified as non-responders on PET response assessment, while only 40% were non-responders by PSA.</div><div>The correlation between PET and PSA was mild <em>(Kendall's tau_b</em> 0.26), and the classification into Responders/Non-responders had only slight agreement (<em>Cohen's kappa</em> 0.30).</div></div><div><h3>Conclusion</h3><div>Choline PET/CT shows low concordance with the PSA values obtained during the follow-up of response to anti-androgen therapy, especially in patients with bone involvement.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500083"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valor clínico de un PET/TC con [18F]F-PSMA negativo en pacientes diagnosticados de cáncer de próstata tratados con prostatectomía con elevación del PSA, inferior a 1 ng/ml, en los resultados de la radioterapia de rescate","authors":"M. Cózar Santiago ,&nbsp;J. García Garzón ,&nbsp;A. Esteban Hurtado ,&nbsp;J. Pastor Peiro ,&nbsp;J. Ferrer Rebolleda","doi":"10.1016/j.remn.2024.500071","DOIUrl":"10.1016/j.remn.2024.500071","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the clinical value of [¹⁸F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1<!--> <!-->ng/mL, on the outcome of salvage radiotherapy.</div></div><div><h3>Method</h3><div>We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51<!--> <!-->ng/mL (range 0.17-1,0<!--> <!-->ng/mL)] who were referred for an [¹⁸F]F-PSMA-PET/CT study.</div><div>The [¹⁸F]F-PSMA-PET/CT scan was negative in 53/98 patients (54.09%). Differences were analysed between those patients who were or were not candidates for pelvic salvage radiotherapy (PSRT) decided upon multidisciplinary committee and patient consent, with a minimum follow-up time for 1<!--> <!-->year. Response to treatment was defined as a 50% reduction in PSA levels. Recurrence was ascertained upon clinical, analytical and imaging follow-up outcomes.</div></div><div><h3>Results</h3><div>54.7% (29/53) of the patients with a negative [¹⁸F]F-PSMA-PET/CT underwent PSRT. Of these, 93.1% (27/29) patients demonstrated response to treatment (PSMA false negatives). The remaining two patients showed fluctuating PSA levels without detecting disease on the [¹⁸F]F-PSMA-PET/CT follow-up study.</div><div>45.3% (24/53) of patients with negative [¹⁸F]F-PSMA-PET/CT did not undergo PSRT. Of these, progressive PSA elevation was observed in 62.5% (15/24) (PSMA false negatives), localising recurrence on the [¹⁸F]F-PSMA-PET/CT follow-up study in 4 patients. The remaining 9 patients (37.5%) showed fluctuating PSA levels without detecting disease on the [¹⁸F]F-PSMA-PET/CT follow-up study.</div><div>Our series confirmed 42 (42.85%) [¹⁸F]F-PSMA-PET/CT false negatives cases.</div></div><div><h3>Conclusion</h3><div>Patients diagnosed with prostate cancer with post-prostatectomy biochemical recurrence and a negative [¹⁸F]F-PSMA-PET/CT study are likely to benefit from pelvic salvage radiotherapy, with response seen in 93.1% of our cases.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500071"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}